NanoVibronix Reports Material Agreements and Equity Sales
Ticker: FEED · Form: 8-K · Filed: Feb 14, 2025 · CIK: 1326706
| Field | Detail |
|---|---|
| Company | Nanovibronix, Inc. (FEED) |
| Form Type | 8-K |
| Filed Date | Feb 14, 2025 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.001, $0.6063, $606, $500,000, $0.4446 |
| Sentiment | neutral |
Sentiment: neutral
Topics: definitive-agreement, acquisition, equity-sale, corporate-action
Related Tickers: NVBX
TL;DR
NVBX filed an 8-K detailing acquisitions, debt, equity sales, and exec changes. Big moves happening.
AI Summary
NanoVibronix, Inc. filed an 8-K on February 14, 2025, reporting several material events. These include entering into a definitive agreement, completing an acquisition, creating a direct financial obligation, and unregistered sales of equity securities. The filing also notes changes in officers and directors, amendments to governing documents, and Regulation FD disclosures.
Why It Matters
This 8-K filing indicates significant corporate actions by NanoVibronix, Inc., including potential acquisitions and financial obligations, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves multiple material events including acquisitions, financial obligations, and equity sales, which inherently carry risks.
Key Players & Entities
- NanoVibronix, Inc. (company) — Filer of the 8-K
- 0001493152-25-006855 (document_id) — Accession Number for the filing
- 20250214 (date) — Filing date
FAQ
What specific definitive agreement did NanoVibronix, Inc. enter into?
The filing indicates the entry into a Material Definitive Agreement, but the specific details of the agreement are not provided in this summary.
What was the nature of the acquisition or disposition of assets?
The filing states the completion of an acquisition or disposition of assets, but the specifics of the transaction are not detailed here.
What is the nature of the direct financial obligation or off-balance sheet arrangement?
The filing reports the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the details are not specified.
Were there any unregistered sales of equity securities?
Yes, the filing explicitly mentions 'Unregistered Sales of Equity Securities' as an item of disclosure.
What changes were made to the rights of security holders?
The filing notes 'Material Modifications to Rights of Security Holders' as an item of disclosure, indicating changes that affect shareholder rights.
Filing Stats: 4,793 words · 19 min read · ~16 pages · Grade level 15.2 · Accepted 2025-02-14 16:05:37
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share NAOV Nasdaq Capital Mark
- $0.6063 — re of Series X Preferred Stock shall be $0.6063. The conversion ratio (the " Conversion
- $606 — X Preferred Stock, initially valued at $606.3756, divided by the conversion price w
- $500,000 — having an aggregate principal amount of $500,000. The closing of the Debenture Financi
- $0.4446 — tor, at the initial conversion price of $0.4446 (the " Conversion Price "), which is su
- $0.088920 — ll not be lower than the floor price of $0.088920. The Debenture bears interest at the ra
- $300 million — quired superDimension for approximately $300 million. As a seasoned entrepreneur, Dr. Besser
Filing Documents
- form8-k.htm (8-K) — 106KB
- ex2-1.htm (EX-2.1) — 681KB
- ex3-1.htm (EX-3.1) — 137KB
- ex4-1.htm (EX-4.1) — 168KB
- ex10-1.htm (EX-10.1) — 294KB
- ex10-2.htm (EX-10.2) — 132KB
- ex23-1.htm (EX-23.1) — 5KB
- ex99-1.htm (EX-99.1) — 488KB
- ex99-2.htm (EX-99.2) — 585KB
- ex99-3.htm (EX-99.3) — 414KB
- ex99-4.htm (EX-99.4) — 24KB
- fin_001.jpg (GRAPHIC) — 28KB
- 0001493152-25-006855.txt ( ) — 3678KB
- naov-20250214.xsd (EX-101.SCH) — 3KB
- naov-20250214_lab.xml (EX-101.LAB) — 33KB
- naov-20250214_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
03
Item 3.03 Material Modification to Rights of Security Holders. The matters described in Item 1.01 of this Current Report on Form 8-K related to the Series X Preferred Stock and the filing of the Certificate of Designations are incorporated herein by reference. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Directors In accordance with the Merger Agreement, on February 14, 2025, immediately after the Second Effective Time, Harold Jacob, Maria Schroeder and Michael Ferguson resigned from the Board and any respective committees thereto of which they were members. The resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices. Appointment of Directors In accordance with the Merger Agreement, on February 14, 2025, immediately after the Second Effective Time, Doron Besser, M.D., and Zeev Rotstein, M.D. were appointed to the Board as directors. Doron Besser is the CEO and President of ENvue Medical. Prior to ENvue, Dr. Besser served as CEO of Angioslide Ltd., a company specializing in innovative, cost-effective angioplasty products. Dr. Besser guided the company through its infancy stages, which included complicated animal and human trials, to FDA clearance, CE approval and initial market penetration in Europe and the US. Dr. Besser also served as VP of Clinical and Marketing and VP of Business Development at superDimension, a leader in minimally-invasive pulmonology devices. Dr. Besser helped lead superDimension from its inception, serving on the core team that identified opportunities within the pulmonology market. In 2012, Covidien acquired superDimension for approximately $300 million. As a seasoned entrepreneur, Dr. Besser specializes in identifying breakthrough technologies and developing them throughout all product development phases, including international